Southern Capital Advisors LLC Buys Shares of 6,422 Stryker Corporation $SYK

Southern Capital Advisors LLC purchased a new stake in Stryker Corporation (NYSE:SYK) during the 1st quarter, HoldingsChannel.com reports. The institutional investor purchased 6,422 shares of the medical technology company’s stock, valued at approximately $2,110,000. Stryker accounts for about 1.0% of Southern Capital Advisors LLC’s investment portfolio, making the stock its 20th biggest holding.

A number of other institutional investors also recently modified their holdings of SYK. VanderPol Investments L.L.C. lifted its position in shares of Stryker by 1.4% during the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after buying an additional 28 shares during the last quarter. KCM Investment Advisors LLC grew its position in Stryker by 1.5% in the fourth quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after acquiring an additional 28 shares during the last quarter. Rossby Financial LCC raised its stake in Stryker by 6.6% during the fourth quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after acquiring an additional 28 shares in the last quarter. Stonebridge Capital Advisors LLC raised its stake in Stryker by 0.4% during the third quarter. Stonebridge Capital Advisors LLC now owns 7,198 shares of the medical technology company’s stock worth $2,661,000 after acquiring an additional 29 shares in the last quarter. Finally, Tcfg Wealth Management LLC lifted its holdings in shares of Stryker by 2.7% in the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after acquiring an additional 29 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. UBS Group reduced their price target on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 17th. Wells Fargo & Company lowered their price objective on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research report on Friday, May 1st. JPMorgan Chase & Co. dropped their price objective on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Truist Financial restated a “hold” rating and issued a $330.00 target price (down from $380.00) on shares of Stryker in a research report on Monday, May 4th. Finally, Citigroup decreased their target price on shares of Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a research note on Tuesday, April 7th. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $395.33.

Stryker Stock Performance

Shares of SYK stock opened at $308.62 on Monday. The firm has a market capitalization of $118.31 billion, a price-to-earnings ratio of 35.72, a PEG ratio of 1.97 and a beta of 0.78. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The business’s 50-day moving average price is $313.81 and its 200-day moving average price is $341.50. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the company earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Equities research analysts forecast that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio is 40.74%.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the sale, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction on Monday, May 11th. The shares were sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the sale, the vice president owned 13,137 shares of the company’s stock, valued at $3,728,937.45. The trade was a 28.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is currently owned by company insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.